Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer
Open Access
- 4 April 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Research
- Vol. 27 (7), 916-932
- https://doi.org/10.1038/cr.2017.51
Abstract
Pancreatic ductal adenocarcinoma (PDAC) driven by oncogenic K-Ras remains among the most lethal human cancers despite recent advances in modern medicine. The pathogenesis of PDAC is partly attributable to intrinsic chromosome instability and extrinsic inflammation activation. However, the molecular link between these two events in pancreatic tumorigenesis has not yet been fully established. Here, we show that intracellular high mobility group box 1 (HMGB1) remarkably suppresses oncogenic K-Ras-driven pancreatic tumorigenesis by inhibiting chromosome instability-mediated pro-inflammatory nucleosome release. Conditional genetic ablation of either single or both alleles of HMGB1 in the pancreas renders mice extremely sensitive to oncogenic K-Ras-driven initiation of precursor lesions at birth, including pancreatic intraepithelial neoplasms, intraductal papillary mucinous neoplasms, and mucinous cystic neoplasms. Loss of HMGB1 in the pancreas is associated with oxidative DNA damage and chromosomal instability characterized by chromosome rearrangements and telomere abnormalities. These lead to inflammatory nucleosome release and propagate K-Ras-driven pancreatic tumorigenesis. Extracellular nucleosomes promote interleukin 6 (IL-6) secretion by infiltrating macrophages/neutrophils and enhance oncogenic K-Ras signaling activation in pancreatic lesions. Neutralizing antibodies to IL-6 or histone H3 or knockout of the receptor for advanced glycation end products all limit K-Ras signaling activation, prevent cancer development and metastasis/invasion, and prolong animal survival in Pdx1-Cre;K-RasG12D/+;Hmgb1−/− mice. Pharmacological inhibition of HMGB1 loss by glycyrrhizin limits oncogenic K-Ras-driven tumorigenesis in mice under inflammatory conditions. Diminished nuclear and total cellular expression of HMGB1 in PDAC patients correlates with poor overall survival, supporting intracellular HMGB1 as a novel tumor suppressor with prognostic and therapeutic relevance in PDAC.Keywords
This publication has 91 references indexed in Scilit:
- The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasiaProceedings of the National Academy of Sciences of the United States of America, 2012
- Endogenous histones function as alarmins in sterile inflammatory liver injury through Toll‐like receptor 9 in miceJournal of Hepatology, 2011
- High-Mobility Group Box 1 Is Essential for Mitochondrial Quality ControlCell Metabolism, 2011
- Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and ProgressionCancer Cell, 2011
- Endogenous HMGB1 regulates autophagyThe Journal of cell biology, 2010
- γH2AX and cancerNature Reviews Cancer, 2008
- High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damageProceedings of the National Academy of Sciences of the United States of America, 2008
- RAGE signaling sustains inflammation and promotes tumor developmentThe Journal of Experimental Medicine, 2008
- Sox9 coordinates a transcriptional network in pancreatic progenitor cellsProceedings of the National Academy of Sciences of the United States of America, 2007
- SOX9 is required for maintenance of the pancreatic progenitor cell poolProceedings of the National Academy of Sciences of the United States of America, 2007